SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24, 2021
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as Specified in its Charter)
|(State or other jurisdiction of incorporation or organization) ||(Commission File Number)||(IRS Employer Identification No.)|
1100 Campus Road
Princeton, NJ 08540
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section12(b) of the Act:
|Title of Each Class||Trading Symbol||Name of Exchange on Which Registered|
|Common Stock, Par Value $.01 Per Share||IART||Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On June 22, 2021, Peter J. Arduini informed Integra LifeSciences Holdings Corporation (the “Company”) of his intention to resign from his position as President and Chief Executive Officer and director of the Company in order to accept an executive position with another company. Mr. Arduini’s resignation will be effective December 31, 2021.
A copy of the press release announcing the resignation of Mr. Arduini is attached to this report as Exhibit 99.1.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
104 Cover Page Interactive Data File (embedded within the inline XRBL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|INTEGRA LIFESCIENCES HOLDINGS CORPORATION|
|Date: June 24, 2021||By:|| /s/ Carrie Anderson|
Executive Vice President, Chief Financial Officer
Integra LifeSciences Announces CEO Succession Plan
Peter Arduini to serve as President and CEO through the end of 2021
Candidate search launched to identify successor
PRINCETON, New Jersey, June 24, 2021 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that Peter Arduini will step down as Chief Executive Officer at the end of 2021 to accept the role of President and Chief Executive Officer of GE Healthcare.
“On behalf of our entire organization, I want to thank Pete for his inspirational leadership and dedication over the past eleven years. Pete has been instrumental in transforming and shaping Integra into the company it is today - a mission-driven organization positively impacting the lives of millions of patients annually,” said Stuart Essig, Chairman of Integra’s Board of Directors.
“Today, Integra is a large and focused company with a strong executive leadership team, highly differentiated products, industry-leading margins, a compelling growth trajectory, and a clear path to sustained shareholder value creation. Pete’s tenure has been exciting and rewarding, and his personal decision comes at a time when Integra is experiencing great momentum and is extremely well-positioned strategically, operationally, and financially. On behalf of the Board, leadership team, and our 3,700 employees globally, we wish Pete all the best in his next endeavor. We are committed to identifying a highly-qualified successor exemplifying our company values who will lead Integra in its next phase of expansion and profitable growth,” concluded Essig.
The Board of Directors has initiated a formal search for a new President and Chief Executive Officer and has appointed a special committee to direct the search and transition process, with the assistance of a leading executive search firm, Heidrick & Struggles, Inc. The process, which the Board expects to conclude this year, will include internal and external candidates. Arduini will remain President and CEO through December 31, 2021 or until a new President and CEO has been named and will ensure that a smooth and seamless transition of responsibilities takes place.
“It has been a privilege and honor to serve as Integra’s President and CEO since 2012 and to work alongside this talented and passionate team. Together, we have accomplished much, including global leadership in neurosurgery with some of the most recognized brands in plastic and reconstructive surgery, and an innovative pipeline to accelerate future growth,” said Peter Arduini, Integra's President and Chief Executive Officer. “I want to personally thank Stuart and the Board for their invaluable guidance and unwavering
partnership over the years, as well as our colleagues, customers, and shareholders for their trust and support. The future is bright for Integra, and I look forward to the many successes this organization will achieve in the years to come.”
About Integra LifeSciences
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, Gentrix®, ICP Express®, Integra®, MatriStem® UBM, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit www.integralife.com.